2024
Cell-specific models reveal conformation-specific RAF inhibitor combinations that synergistically inhibit ERK signaling in pancreatic cancer cells
Sevrin T, Imoto H, Robertson S, Rauch N, Dyn'ko U, Koubova K, Wynne K, Kolch W, Rukhlenko O, Kholodenko B. Cell-specific models reveal conformation-specific RAF inhibitor combinations that synergistically inhibit ERK signaling in pancreatic cancer cells. Cell Reports 2024, 43: 114710. PMID: 39240715, PMCID: PMC11474227, DOI: 10.1016/j.celrep.2024.114710.Peer-Reviewed Original ResearchConceptsPancreatic ductal adenocarcinomaResistance to RAFResistant PDAC cellsPancreatic cancer cellsPancreatic ductal adenocarcinoma cell linesProtein expression profilesTumor-specific variationsIsogenic pairsCell-specific modelsConformational specificityERK signalingInhibitor combinationsERK pathwayKRAS mutationsTargeted therapyExpression profilesMEK inhibitorsDuctal adenocarcinomaCancer cellsKRAS mutantPhospho-ERKCell linesPDAC cellsCell viabilityDifferential sensitivityCell State Transition Models Stratify Breast Cancer Cell Phenotypes and Reveal New Therapeutic Targets
Rukhlenko O, Imoto H, Tambde A, McGillycuddy A, Junk P, Tuliakova A, Kolch W, Kholodenko B. Cell State Transition Models Stratify Breast Cancer Cell Phenotypes and Reveal New Therapeutic Targets. Cancers 2024, 16: 2354. PMID: 39001416, PMCID: PMC11240448, DOI: 10.3390/cancers16132354.Peer-Reviewed Original ResearchControl of cell movementCell linesCell statesLuminal BC cellsControl cell phenotypeWaddington landscapeTissue-derived cell linesCell movementOncogenic transformationSmall molecule inhibitorsSignaling nodeBC cell linesExpression profilesPerturbation datasetsNormal cell stateMolecule inhibitorsBC cellsCell phenotypeBasal BCBC subtypesBreast cancerOncogenic driversCellsCurrent biologicsBreast tissue cells
2018
PO-136 Studying pathway interactions and dynamics to predict cell responses to chemotherapeutic treatment in breast cancer cells
Tuffery L, Kholodenko B, Kolch W, Halasz M, Fey D. PO-136 Studying pathway interactions and dynamics to predict cell responses to chemotherapeutic treatment in breast cancer cells. ESMO Open 2018, 3: a279. DOI: 10.1136/esmoopen-2018-eacr25.660.Peer-Reviewed Original ResearchBreast cancer cell linesDoxorubicin treatmentCancer cell linesCell linesDifferent breast cancer cell linesBreast cancer cellsMCF10A cellsDifferent mutation patternsMechanism of actionPhosphorylation of JNKBreast cancer tumor samplesCommon cancerPatient responseTreatment strategiesBreast cancerTreatment responseChemotherapeutic treatmentCell responsesFlow cytometryTumor samplesWestern blotNon-cancerous cellsChemotherapeutic drugsPathway interactionsCancer cells